Assessment of drug activity and proliferation ex vivo for prediction of outcome in aggressive non-Hodgkin's lymphomas

Acta Oncologica

Volumn 41, Issue 1, 2002, Pages 36-43

  Rehn Ericsson, Suzanne M ^a   Larsson, Rolf L ^a   Nygren, H Peter ^a   Sundström, Christer ^a   Glimelius, Bengt L G ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CELLS; PATIENT TREATMENT; TUMORS;

PROGNOSTIC INFORMATIONS;

DRUG PRODUCTS;

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; FEMALE; HUMAN; IMMUNOPHENOTYPING; MALE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BIOPSY; BLEOMYCIN; CELL DIVISION; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; KI-67 ANTIGEN; LYMPHOMA, NON-HODGKIN; METHOTREXATE; MITOTIC INDEX; NEOPLASM STAGING; PREDNISONE; SURVIVAL RATE; TENIPOSIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036221463     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418602317314046     Document Type: Article

References (34)

1. High-grade non-Hodgkin lymphoma stage I. A retrospective study of treatment outcome and prognostic factors in 213 patients
2. Stage I high-grade non-Hodgkin's lymphoma
3. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma
4. A predictive model for aggressive non-Hodgkin's lymphoma
5. High-dose therapy for lymphoma
6. Remission inversion and no transplant-related mortality. A single center experience of autologous stem cell transplantation in malignant lymphoma
7. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by monoclonal antibody Ki-67
8. A comparative study of proliferation-associated parameters in B-cell non-Hodgkin lymphoma
9. Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers
10. MIB-1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas
11. Tumour inhomogeneities on magnetic resonance imaging, a new prognostic factor with prognostic information in non-Hodgkin's lymphoma
12. What is cancer chemotherapy
13. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA)
14. A revised European-American classification of lymphoid neoplasm: A proposal from the international lymphoma study group
15. Report of the Committee in Hodgkin's Disease Staging Classification
16. CHOP versus CHOP-M in the treatment of high-grade malignant non-Hodgkin's lymphomas in adults: A Swedish national randomized study
17. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphocytic leukemia
18. New histochemical test for glycin and mycin
19. Differential staining of mitosis in tissue sections and cultured cells by a modified methenamine-silver method
20. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
21. Detection of tumor specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients
22. In vitro determination of drug response: A discussion of clinical applications
23. Properties of verapamil hypersensitive multidrug-resistant Chinese hamster ovary cells
24. Predictive assays for drug and radiation resistance
25. Predictions of individual response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model
26. Drug sensitivity testing of tumor cells from patients with acute leukemia and non-Hodgkin lymphoma using a fluorometric microculture cytotoxicity assay
27. Laboratory prediction of clinical chemotherapeutic drug resistance: A working model exemplified by acute leukemia
28. In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay
29. Computed tomography in malignancy grading and prognostic prediction of non-Hodgkin lymphoma
30. The labelling index: A prognostic factor in head and neck carcinoma
31. Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer
32. Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases
33. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia